Safety and efficacy of ezetimibe/simvastatin combination versus atorvastatin alone in adults ≥65 years of age with hypercholesterolemia and with or at moderately high/high risk for coronary heart disease (the VYTELD study)

American Journal of Cardiology

Volumn 106, Issue 9, 2010, Pages 1255-1263

  Foody, Joanne M ^a   Brown, W Virgil ^b   Zieve, Franklin ^c   Adewale, Adeniyi J ^d   Flaim, Doreen ^d   Lowe, Robert S ^d   Jones Burton, Charlotte ^d   Tershakovec, Andrew M ^d  

^a BRIGHAM AND WOMEN S HOSPITAL   (United States)

^b EMORY UNIVERSITY SCHOOL OF MEDICINE   (United States)

^c VIRGINIA COMMONWEALTH UNIVERSITY   (United States)

^d MERCK RESEARCH LABORATORIES   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

APOLIPOPROTEIN A1; APOLIPOPROTEIN B; ATORVASTATIN; C REACTIVE PROTEIN; EZETIMIBE PLUS SIMVASTATIN; HIGH DENSITY LIPOPROTEIN CHOLESTEROL; LIPOPROTEIN; LOW DENSITY LIPOPROTEIN CHOLESTEROL; TRIACYLGLYCEROL; VERY LOW DENSITY LIPOPROTEIN CHOLESTEROL;

AGED; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; CHOLESTEROL BLOOD LEVEL; CLINICAL TRIAL; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG ERUPTION; DRUG FATALITY; DRUG HYPERSENSITIVITY; DRUG SAFETY; DRUG TOLERABILITY; DRUG WITHDRAWAL; FEMALE; GALLBLADDER DISEASE; GASTROINTESTINAL SYMPTOM; HUMAN; HYPERCHOLESTEROLEMIA; ISCHEMIC HEART DISEASE; MAJOR CLINICAL STUDY; MALE; MULTICENTER STUDY; PATIENT COMPLIANCE; PRIORITY JOURNAL; PROTEIN BLOOD LEVEL; RANDOMIZED CONTROLLED TRIAL; SIDE EFFECT; TOXIC HEPATITIS; TRIACYLGLYCEROL BLOOD LEVEL; UNSPECIFIED SIDE EFFECT;

AGED; ANTICHOLESTEREMIC AGENTS; AZETIDINES; BIOLOGICAL MARKERS; CORONARY DISEASE; DOSE-RESPONSE RELATIONSHIP, DRUG; DOUBLE-BLIND METHOD; DRUG THERAPY, COMBINATION; FEMALE; HEPTANOIC ACIDS; HUMANS; HYPERCHOLESTEROLEMIA; LIPIDS; LOGISTIC MODELS; MALE; PYRROLES; RISK FACTORS; SIMVASTATIN; TREATMENT OUTCOME;

EID: 77958609555     PISSN: 00029149     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.amjcard.2010.06.051     Document Type: Article

References (23)

1. C.M. Ballantyne, J. Houri, A. Notarbartolo, L. Melani, L.J. Lipka, R. Suresh, S. Sun, A.P. LeBeaut, P.T. Sager, and E.P. Veltri Effect of ezetimibe coadministered with atorvastatin in 628 patients with primary hypercholesterolemia: a prospective, randomized, double-blind trial Circulation 107 2003 2409 2415
2. M.H. Davidson, C.M. Ballantyne, B. Kerzner, L. Melani, P.T. Sager, L. Lipka, J. Strony, R. Suresh, and E. Veltri Efficacy and safety of ezetimibe coadministered with statins: randomised, placebo-controlled, blinded experience in 2382 patients with primary hypercholesterolemia Int J Clin Pract 58 2004 746 755
3. A.L. Catapano Perspectives on low-density lipoprotein cholesterol goal achievement Curr Med Res Opin 25 2009 431 447
4. L. Lipka, P. Sager, J. Strony, B. Yang, R. Suresh, and E. Veltri Efficacy and safety of coadministration of ezetimibe and statins in elderly patients with primary hypercholesterolaemia Drugs Aging 21 2004 1025 1032 (Pubitemid 40075727)
5. T. Pearson, M. Denke, P. McBride, W.P. Battisti, W.E. Brady, and J. Palmisano Effectiveness of the addition of ezetimibe to ongoing statin therapy in modifying lipid profiles and attaining low-density lipoprotein cholesterol goals in older and elderly patients: subanalyses of data from a randomized, double-blind, placebo-controlled trial Am J Geriatr Pharmacother 3 2005 218 228
6. J.G. Robinson, M. Davidson, A. Shah, J. Lin, D. Neff, P. DeLucca, J.E. Tomassini, E. Veltri, and A.M. Tershakovec Efficacy and safety of ezetimibe and ezetimibe plus statin therapy in patients aged under 65, 6574 and 75 years and older J Aging Health 3 2007 691 705
7. F. Zieve, N.K. Wenger, O. Ben Yehuda, C. Constance, S. Bird, R. Lee, M.E. Hanson, C. Jones-Burton, and A.M. Tershakovec Safety and efficacy of ezetimibe added to atorvastatin versus up titration of atorvastatin to 40 mg in patients > or = 65 years of age (from the ZETia in the ELDerly [ZETELD] study) Am J Cardiol 105 2010 656 663
8. S.M. Grundy, J.I. Cleeman, C.N. Merz, H.B. Brewer Jr, L.T. Clark, D.B. Hunninghake, R.C. Pasternak, S.C. Smith Jr, and N.J. Stone Implications of recent clinical trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines J Am Coll Cardiol 44 2004 720 732
9. S.C. Smith Jr, J. Allen, S.N. Blair, R.O. Bonow, L.M. Brass, G.C. Fonarow, S.M. Grundy, L. Hiratzka, D. Jones, H.M. Krumholz, L. Mosca, R.C. Pasternak, T. Pearson, M.A. Pfeffer, and K.A. Taubert AHA/ACC guidelines for secondary prevention for patients with coronary and other atherosclerotic vascular disease: 2006 update: endorsed by the National Heart, Lung, and Blood Institute Circulation 113 2006 2363 2372 (Pubitemid 43947981)
10. Third Report of the National Cholesterol Education Program (NCEP) Expert panel on detection, evaluation, and treatment of high blood cholesterol in adults (Adult Treatment Panel III) final report Circulation 106 2002 3143 3421
11. I. Graham, D. Atar, K. Borch-Johnsen, G. Boysen, G. Burell, R. Cifkova, J. Dallongeville, G. De Backer, S. Ebrahim, B. Gjelsvik, C. Herrmann-Lingen, A. Hoes, S. Humphries, M. Knapton, J. Perk, S.G. Priori, K. Pyorala, Z. Reiner, L. Ruilope, S. Sans-Menendez, W.S. Op Reimer, P. Weissberg, D. Wood, J. Yarnell, J.L. Zamorano, E. Walma, T. Fitzgerald, M.T. Cooney, A. Dudina, A. Vahanian, J. Camm, R. De Caterina, V. Dean, K. Dickstein, C. Funck-Brentano, G. Filippatos, I. Hellemans, S.D. Kristensen, K. McGregor, U. Sechtem, S. Silber, M. Tendera, P. Widimsky, J.L. Zamorano, A. Altiner, E. Bonora, P.N. Durrington, R. Fagard, S. Giampaoli, H. Hemingway, J. Hakansson, S.E. Kjeldsen, L. Larsen, G. Mancia, A.J. Manolis, K. Orth-Gomer, T. Pedersen, M. Rayner, L. Ryden, M. Sammut, N. Schneiderman, A.F. Stalenhoef, L. Tokgozoglu, O. Wiklund, and A. Zampelas European guidelines on cardiovascular disease prevention in clinical practice: full text. Fourth Joint Task Force of the European Society of Cardiology and other societies on cardiovascular disease prevention in clinical practice (constituted by representatives of nine societies and by invited experts) Eur J Cardiovasc Prev Rehabil 14 Suppl 2 2007 S1 S113
12. R. McPherson, J. Frohlich, G. Fodor, J. Genest Canadian Cardiovascular Society Canadian Cardiovascular Society position statementrecommendations for the diagnosis and treatment of dyslipidemia and prevention of cardiovascular disease Can J Cardiol 22 2006 913 927
13. Heart Protection Study Collaborative Group MRC/BHF Heart Protection Study of cholesterol lowering with simvastatin in 20,536 high-risk individuals: a randomised placebo-controlled trial Lancet 360 2002 7 22
14. J. Shepherd, G.J. Blauw, M.B. Murphy, E.L. Bollen, B.M. Buckley, S.M. Cobbe, I. Ford, A. Gaw, M. Hyland, J.W. Jukema, A.M. Kamper, P.W. Macfarlane, A.E. Meinders, J. Norrie, C.J. Packard, I.J. Perry, D.J. Stott, B.J. Sweeney, C. Twomey, and R.G. Westendorp Pravastatin in elderly individuals at risk of vascular disease (PROSPER): a randomised controlled trial Lancet 360 2002 1623 1630
15. P. Deedwania, P.H. Stone, C.N. Bairey Merz, J. Cosin-Aguilar, N. Koylan, D. Luo, P. Ouyang, R. Piotrowicz, K. Schenck-Gustafsson, P. Sellier, J.H. Stein, P.L. Thompson, and D. Tzivoni Effects of intensive versus moderate lipid-lowering therapy on myocardial ischemia in older patients with coronary heart disease: results of the Study Assessing Goals in the Elderly (SAGE) Circulation 115 2007 700 707
16. N.K. Choudhry, S. Setoguchi, R. Levin, W.C. Winkelmayer, and W.H. Shrank Trends in adherence to secondary prevention medications in elderly post-myocardial infarction patients Pharmacoepidemiol Drug Saf 17 2008 1189 1196
17. D.T. Ko, M. Mamdani, and D.A. Alter Lipid-lowering therapy with statins in high-risk elderly patients: the treatment-risk paradox JAMA 291 2004 1864 1870
18. B.A. Steinberg, D.L. Bhatt, S. Mehta, P.A. Poole-Wilson, P. O'Hagan, G. Montalescot, C.M. Ballantyne, and C.P. Cannon Nine-year trends in achievement of risk factor goals in the US and European outpatients with cardiovascular disease Am Heart J 156 2008 719 727
19. D.D. Waters, C. Brotons, C.W. Chiang, J. Ferrieres, J. Foody, J.W. Jukema, R.D. Santos, J. Verdejo, M. Messig, R. McPherson, K.B. Seung, and L. Tarasenko Lipid treatment assessment project 2: a multinational survey to evaluate the proportion of patients achieving low-density lipoprotein cholesterol goals Circulation 120 2009 28 34
20. J.G. Robinson, C.M. Ballantyne, S.M. Grundy, W.A. Hsueh, H.H. Parving, J.B. Rosen, A.J. Adewale, A.B. Polis, J.E. Tomassini, and A.M. Tershakovec Lipid-altering efficacy and safety of ezetimibe/simvastatin versus atorvastatin in patients with hypercholesterolemia and the metabolic syndrome (from the VYMET study) Am J Cardiol 103 2009 1694 1702
21. A.L. Catapano, M.H. Davidson, C.M. Ballantyne, W.E. Brady, R.A. Gazzara, J.E. Tomassini, and A.M. Tershakovec Lipid-altering efficacy of the ezetimibe/simvastatin single tablet versus rosuvastatin in hypercholesterolemic patients Curr Med Res Opin 22 2006 2041 2053
22. Lipitor (Atorvastatin Calcium) Tablets for Oral Administration [Package Insert] 2009 Pfizer New York
23. Vytorin (Ezetimibe/Simvastatin) [Package Insert] 2009 Merck/Schering-Plough Pharmaceuticals North Wales, PA